// App-Quantinova.ai

1330 : The JAK Inhibitor Ruxolitinib Is Effective in Treating T Cell Acute Lymphoblastic Leukemia with Gain of Function Mutations in IL-7R Alpha

Researchers

Presenter

  • Emilee Senkevitch

Principal Investigators

  • Julie Hixon

  • Caroline Andrews

  • Joao T Barata

  • Wenqing Li

  • Scott Durum

Medical Centers

  • Cancer and Inflammation Program, National Cancer Institute, Frederick, MD

  • Instituto de Medicina Molecular, Faculdade de Medicina Da Universidade de Lisboa, Rheumatology Research Unit, Lisbon, Portugal

Locations

  • United States

  • Portugal

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Solid malignancies

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • Interleukin-7

  • Signal transducer and activator of transcription 5

Drug/Treatment

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved